Luther R R, Glassman H N, Estep C B, Schmitz P J, Horton J K, Jordan D C
Department of Clinical Research, Abbott Laboratories, IL 60064.
Am J Hypertens. 1988 Jul;1(3 Pt 3):237S-240S. doi: 10.1093/ajh/1.3.237s.
The long-term treatment of essential hypertension with terazosin, a new once-a-day alpha 1-adrenergic blocking agent, was evaluated in 364 hypertensive patients who received total daily doses of 1 to 40 mg for 3 weeks to 56 months. Consistent mean decreases in supine and standing systolic and diastolic blood pressures were observed throughout the study for patients treated with terazosin as monotherapy (supine, 9 to 12/10 to 13 mm Hg; and standing, 12 to 18/11 to 14 mm Hg) or in combination with other antihypertensive agents (supine, 12 to 16/12 to 15 mm Hg; and standing, 16 to 22/13 to 19 mm Hg). The most commonly reported adverse experiences were dizziness, headache, asthenia, cold symptoms, and nasal congestion. Adverse effects and metabolic disorders often associated with diuretics and beta blockers such as sexual dysfunction, hyperglycemia, hyperuricemia, hypokalemia, or adverse lipid effects were seen infrequently during long-term treatment with terazosin as monotherapy. Overall, terazosin was shown to be effective, safe, and well tolerated by most patients.
对364例高血压患者进行了研究，评估新型每日一次α1肾上腺素能阻滞剂特拉唑嗪对原发性高血压的长期治疗效果。这些患者每日总剂量为1至40毫克，治疗时间为3周至56个月。在整个研究过程中，接受特拉唑嗪单药治疗的患者（仰卧位收缩压和舒张压平均下降9至12/10至13毫米汞柱；站立位收缩压和舒张压平均下降12至18/11至14毫米汞柱）或与其他抗高血压药物联合使用的患者（仰卧位收缩压和舒张压平均下降12至16/12至15毫米汞柱；站立位收缩压和舒张压平均下降16至22/13至19毫米汞柱），仰卧位和站立位的收缩压和舒张压均持续出现均值下降。最常报告的不良事件为头晕、头痛、乏力、感冒症状和鼻充血。在特拉唑嗪单药长期治疗期间，很少出现利尿剂和β受体阻滞剂常伴有的不良反应及代谢紊乱，如性功能障碍、高血糖、高尿酸血症、低钾血症或不良血脂影响。总体而言，特拉唑嗪对大多数患者显示出有效、安全且耐受性良好。
